Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
gptkb:parathyroid_hormone
|
| gptkbp:clinicalTrials |
gptkb:Canada
gptkb:United_States gptkb:OPKO_Health,_Inc. Europe Phase 3 improved quality of life positive efficacy results reduced hypocalcemia episodes |
| gptkbp:collaborations |
academic institutions
clinical research organizations healthcare_providers |
| gptkbp:date |
FDA_approved
|
| gptkbp:developedBy |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:dosageForm |
solution for injection
|
| gptkbp:drugInterdiction |
hormones
endocrine therapy |
| gptkbp:firstAppearance |
2019-10-25
|
| gptkbp:formulation |
injectable solution
|
| gptkbp:future_plans |
global market expansion
combination therapies new formulations expanded indications |
| gptkbp:hasPopulation |
adults
pediatric patients |
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 420
|
| gptkbp:insuranceAccepted |
covered by some insurance plans
|
| gptkbp:label |
contains contraindications
contains instructions for use contains warnings for allergic reactions contains warnings for hypocalcemia |
| gptkbp:mandates |
treatment of hypoparathyroidism
|
| gptkbp:manufacturer |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:market |
available in pharmacies
available through specialty pharmacies |
| gptkbp:marketedAs |
Tymozin
|
| gptkbp:offers |
high cost
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchFocus |
patient adherence
long-term safety comparative effectiveness dosing strategies |
| gptkbp:route |
subcutaneous injection
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
fatigue
headache nausea injection site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
hypoparathyroidism
|
| gptkbp:triggerType |
replaces parathyroid hormone
|